A state-of-the-art Gene Therapy facility operated by Meira GTx was formerly introduced by An Taoiseach on September 16th, 2022 in Shannon, Ireland.

The 150,000 sq ft site has at its disposal three different facilities designed for viral vector production (for clinical and commercial supply), plasmid DNA manufacture (a starting point for viral vector technology), and advanced biochemical quality control testing. 

The Shannon site is unique in the way it integrates and streamlines all stages of producing gene therapy products, therefore optimizing the entire process, reducing costs, and regulatory risks, and accelerating the development and delivery of gene therapy products to patients.

According to Alexandria Forbes, president and CEO of Meira GTx, the new site will significantly reduce the time to deliver potentially curative treatments for patients with serious diseases. The focus is on patients dealing with a variety of genetic and non-hereditary illnesses such as inherited vision loss, salivary-gland conditions, some cancers, and neurological diseases such as Parkinson’s.

Read the full press release in the link below.